Navigation Links
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Date:6/12/2008

with primary insomnia. The trial evaluated standard PSG measurements of sleep, such as WASO, WTDS, number of awakenings, number of arousals, total sleep time and latency to persistent sleep, and enrolled a total of 173 male and female patients, ages 18-64, in 24 sleep research centers in the United States. To qualify for enrollment, patients were required to have paired screening PSGs that demonstrated an average WASO greater than or equal to 60 minutes, with neither PSG less than 45 minutes.

Every patient received both active doses of APD125 (10 mg and 40 mg) and placebo in random order for one week, separated by a seven to nine day washout period between each dosing period. Efficacy was measured objectively by averaging PSG values for N 1/2 and for N 6/7, versus baseline values obtained by averaging results from the screening PSGs.

About APD125

Discovered by Arena, APD125 is a novel and oral selective inverse agonist of the 5-HT2A serotonin receptor. The vast majority of approved drugs for insomnia work by activating the GABA-A receptor complex in the brain, causing a general suppressive effect on the central nervous system, or CNS. These GABAergic drugs are generally associated with CNS side effects, including a sensation of dullness and lethargy upon awakening, often referred to as the "hangover effect." Other potential problems associated with the GABAergic drugs include the risk of developing tolerance and drug dependency in at-risk populations. In addition, GABAergic drugs are scheduled controlled substances by the Drug Enforcement Administration due to their potential for abuse.

APD125 acts through a different mechanism than currently marketed insomnia drugs. Arena believes that by selectively targeting the 5-HT2A receptor, APD125 blocks one of several CNS activating pathways rather than initiating a general CNS suppressive effect. Because of the different mechanism of action, APD125 may not have the side effects or abuse potenti
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
4. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
5. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
7. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
10. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
11. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... --  Mallinckrodt plc (NYSE: MNK ), a leading ... at the Bank of America Merrill Lynch 2015 Health Care ... Las Vegas, Nev. Matthew ... Cole Lannum , Senior Vice President of Investor Strategy ... session scheduled to begin at 3 p.m. Eastern / noon ...
(Date:5/4/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ... of its fiscal year ending June 30, 2015. ... noted, "With the close of the Novartis-GSK transaction, ... innovative oncology products in Phase 3, with plans ... These transformative transactions have accelerated our path to ...
(Date:5/4/2015)... , May 4, 2015  Prometheus Research ... the American Optometric Association (AOA) to build a ... outcomes for the millions of patients treated by ... Outcomes Registry for Eyecare (MORE) will leverage ... facilitate efficient secondary uses of essential health and ...
Breaking Medicine Technology:Mallinckrodt To Present At Bank Of America Merrill Lynch 2015 Health Care Conference 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 10American Optometric Association, Prometheus Research to Create Transformative Health Outcomes Registry 2
... Sept. 14 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Business Development of BioMarin, will present a company update at ... on Tuesday, September 21, 2010 at 3:30 p.m. ET.   ... of the conference call via the investor section of the ...
... WORCESTER, Mass., Sept. 14 Generex Biotechnology Corporation (Nasdaq: ... in drug delivery for metabolic diseases through the inner ... entered into an exclusive Product Licensing & Distribution Agreement ... marketing, distribution and sale of Generex Oral-lyn™, the Company,s ...
Cached Medicine Technology:BioMarin to Present at the UBS Global Life Sciences Conference 2Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile 2Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile 3
(Date:5/4/2015)... Elisabeth Rosenthal’s article* on “balance billing” ... the healthcare fraternity as well as patients about ... of balance billing. In definition, balance billing is ... patient for the difference between what the patient's ... provider chooses to charge. Rosenthal’s article talks about ...
(Date:5/4/2015)... May 04, 2015 For partners who’d ... new lubricant -- Astroglide TTC™ (Trying to Conceive) ... and alter pH levels, Astroglide TTC™ is specially formulated ... According to the Centers for Disease Control, an average ... getting pregnant or sustaining a pregnancy, and over ...
(Date:5/4/2015)... Peacock Alley knows we all ... “My mother was the most beautiful woman I ever saw.” ... feminine prints and textures to remind her just ... the Eloise Robe to get you there. The beautiful Monet-inspired ... and tapered waist. It is available in small/medium or large/extra ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 Barbara Crone has joined ... enhance the well being of the men, women and families who ... followed by providing care for families in the home. ... Nurse Practitioner began wondering if I could complete their care with ... own children with my mentor Nurse Midwife, I knew it was ...
(Date:5/3/2015)... Indiana (PRWEB) May 03, 2015 Indiana ... Service Provider announces Bank Computer Services, Inc (BCS) has ... Prout, BCS’ President states, “The technology, service, and working ... really like is the local feel you get with ... and managed company; IFN makes local decisions and operates ...
Breaking Medicine News(10 mins):Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 3
... women should consider the real cost of the procedure beyond the ... surgeon, advises of the importance of choosing a cosmetic surgeon wisely based ... ... Paramus, NJ (PRWeb) January 27, 2009 - You may be under the ...
... Solutions ( http://www.ahsrcm.com ), a leading provider of ... it has entered into an agreement with Staten ... of physician billing and A/R management services for ... the agreement, AHS will acquire the existing SIUH ...
... Attorneys representing individual physicians and the physician partnership ... praised today,s announcement that Texas Attorney General Greg ... similar violations of the state antitrust laws.The Attorney ... an agreed injunction prohibiting Memorial Hermann from engaging ...
... Withholding Eucharist From Pro-Abortion Catholic PelosiWASHINGTON, Jan. 26 ... Kenney issued the following statement today regarding Speaker of ... Sunday. Rep. Pelosi stated that the millions of dollars ... "reduce costs to the states and to the federal ...
... American Heart Association science advisory concludes that omega-6 fatty acids ... are a beneficial part of a heart-healthy eating plan. ... issue of Circulation: Journal of the American Heart Association. ... Fatty Acids Click here for the full ...
... be hidden in DNA , , MONDAY, Jan. 26 (HealthDay News) ... make you human are genes that may determine whether you ... two types of twins shows that genetics might affect social ... are closing in on some of those "personality" genes. , ...
Cached Medicine News:Health News:Interested in Breast Augmentation, New Jersey? Be Sure You Know the “Real Cost” 2Health News:Interested in Breast Augmentation, New Jersey? Be Sure You Know the “Real Cost” 3Health News:Interested in Breast Augmentation, New Jersey? Be Sure You Know the “Real Cost” 4Health News:Staten Island University Hospital Chooses Advantedge Healthcare Solutions for Employed Physician Billing 2Health News:Staten Island University Hospital Chooses Advantedge Healthcare Solutions for Employed Physician Billing 3Health News:Staten Island University Hospital Chooses Advantedge Healthcare Solutions for Employed Physician Billing 4Health News:Lawyers React to Texas Attorney General's Lawsuit, Settlement Against Houston's Memorial Hermann 2Health News:American Life League Statement on Pelosi's State-Enforced War on Preborn Babies 2Health News:Popular or Not? Your Genes May Help Decide 2Health News:Popular or Not? Your Genes May Help Decide 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: